Ma Carmen Martin

Ma Carmen Martin

Auto-generated profile, based on publicly available information

Ma Carmen Martin

Centro de Hemoterapia y Hemodonación de Castilla y León

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
Elena UrcelayElena Urcelay
Elena Urcelay
JMJuan L Mendoza
Juan L Mendoza
CMCarmen M Martín
Carmen M Martín
AMAna Mas
Ana Mas
AMAlfonso Martínez
Alfonso Martínez
ECEmilio G de la Concha
Emilio G de la Concha
Background. The multidrug resistance MDR1 gene codes for a membrane transporter associated with inflammatory bowel disease. The polymorphism Ala893Ser/Thr (G267

23 October 2007 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
MMM. Carmen Martín
M. Carmen Martín
AMAlfonso Martinez
Alfonso Martinez
JMJ. Luis Mendoza
J. Luis Mendoza
CTCarlos Taxonera
Carlos Taxonera
MDManuel Díaz-Rubio
Manuel Díaz-Rubio
Elena UrcelayElena Urcelay
Elena Urcelay

14 August 2020 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
Aurora Jurado RogerAurora Jurado Roger
Aurora Jurado Roger
MMMaría C. Martín
María C. Martín
CACristina Abad-Molina
Cristina Abad-Molina
AOAntonio Orduña
Antonio Orduña
AMAlba Martínez
Alba Martínez
JMJuan Molina
Juan Molina
Background: The SARS-CoV-2 infection has widely spread to become the greatest public health challenge to date, the COVID-19 pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out by local health authorities. The Spanish case-fatality rate is 11.22%, far higher than those reported in Asia or by other European countries. A multicentre retrospective study of demographic, clinical, laboratory and immunological features of 584 Spanish COVID-19 hospitalized patients and their outcomes was performed. The use of renin-angiotensin system blockers was also analysed as a risk factor. Results: In this study, 27.4% of cases presented a mild course, 42.1% a moderate one and for 30.5% of cases, the course was severe. Ages ranged from 18 to 98 (average 63). Almost 60 % (59.8%) of patients were male. Interleukin 6 was higher as severity increased. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19, and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of angiotensin-converting enzyme inhibitors was associated with a better prognosis. The angiotensin II receptor blocker use was associated with a more severe course. Conclusions: Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and the clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for the hampering of immune system effectors. The adaptive immunity would become exhausted and a strong but ineffective and almost deleterious innate response would account for COVID-19 severity. Angiotensin-converting enzyme inhibitors used by hypertensive patients have a protective effect in regards to COVID-19 severity in our series. Conversely, patients on angiotensin II receptor blockers showed a severer disease.

1 March 2007 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
AMAlfonso Martínez
Alfonso Martínez
MSMarta Sánchez-Lopez
Marta Sánchez-Lopez
JVJezabel Varadé
Jezabel Varadé
AMAna Mas
Ana Mas
MMM Carmen Martín
M Carmen Martín
Elena UrcelayElena Urcelay
Elena Urcelay
Objectives: Expression of major histocompatibility complex (MHC) class II genes is almost exclusively regulated by the class II transactivator. A promoter polymorphism (−168A/G, rs3087456) in the MHC2TA gene was associated with increased susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction in a northern European population. However, no evidence of association of this MHC2TA variant with the two autoimmune diseases could be subsequently detected in independent cohorts. Aim: To test the aforementioned single nucleotide polymorphism and another G→C change (nt1614 from coding sequence, rs4774) to analyse the haplotype pattern in this MHC2TA gene. Methods: A case–control study was performed with 350 patients with rheumatoid arthritis, 396 patients with multiple sclerosis, 663 patients with inflammatory bowel disease (IBD) and 519 healthy controls from Madrid. Genotyping was ascertained by using TaqMan assays-on-demand on a 7900HT analyser, following the manufacturer’s suggestions (Applied Biosystems, Foster City, California, USA). Haplotypes were inferred with the expectation–maximisation algorithm implemented by the Arlequin software. Results: No independent association with these autoimmune diseases was found for either polymorphism in the Spanish cohorts tested. However, when haplotypes were compared between patients with rheumatoid arthritis and controls, a significant difference in their overall frequency distribution was observed, evidencing a protective haplotype (−168A/1614C, p = 0.006; odds ratio (OR) 0.7) and a risk haplotype (−168G/1614C, p = 0.019; OR 1.6). Patients with multiple sclerosis mirrored these results, but no effect on IBD was identified. Conclusions: The MHC2TA gene influences predisposition to rheumatoid arthritis and multiple sclerosis, but not to IBD. The −168G allele is not an aetiological variant in itself, but a genetic marker of susceptibility/protection haplotypes.

19 March 2005 in Nitric Oxide
Verified
Journal Article
Closed access
MMMa del Carmen Martín
Ma del Carmen Martín
GBGloria Balfagón
Gloria Balfagón
NMNuria Minoves
Nuria Minoves
JBJavier Blanco-Rivero
Javier Blanco-Rivero
MFMercedes Ferrer
Mercedes Ferrer

7 December 2005 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
AMAlfonso Martínez
Alfonso Martínez
MMMaria del Carmen Martín
Maria del Carmen Martín
JMJuan L Mendoza
Juan L Mendoza
CTCarlos Taxonera
Carlos Taxonera
MDManuel Díaz-Rubio
Manuel Díaz-Rubio
Elena UrcelayElena Urcelay
Elena Urcelay
The SLC22A4 and SLC22A5 genes within the IBD5 risk locus encode the organic cation transporters OCTN1 and OCTN2. Two variants, 1672C>T in SLC22A4 and −207G>C in SLC22A5, were shown to alter these genes' functions and were identified as genetic susceptibility factors for Crohn's disease (CD). We pursued to check both putative etiologic variants in an independent population through a case–control study with 309 Spanish CD patients and 408 ethnically matched healthy subjects. Both polymorphisms were found in partial linkage disequilibrium (D′=0.86). The separate analysis of each OCTN variant evidenced no association. However, when the simultaneous presence of mutant variants in both genes was analyzed, an effect on CD susceptibility was observed (P=0.026, odds ratio (OR) (95% confidence interval (CI))=1.59 (1.03–2.45)). The previously described predisposition conferred by the 5q31-risk haplotype increased in the absence of the etiologic 1672T and −207C alleles (P=0.0006, OR (95% CI)=10.14 (1.97–98.04)). Moreover, the risk contributed by these polymorphisms was higher in the IBD5 wild-type population (P=0.003, OR (95% CI)=2.65 (1.32–5.35)), arguing against the exclusive etiological role of the OCTN variants. The haplotype pattern inferred led to the consideration of these variants as susceptibility markers only in a defined genetic context. Our data support the interpretation of the 1672C>T SLC22A4 and −207G>C SLC22A5 polymorphisms as genetic markers of susceptibility/protection haplotypes.